Endocrine Abstracts

Contents

• 23rd National Conference of the UK and Ireland Neuroendocrine Tumour Society 2025
• • Oral Communications
  • • Does surgical resection improve survival of pancreatic neuroendocrine tumours (panNET) less than 2 cm? a population-based study of 4,114 patients comparing England and the USA

      ea0114oc1
    • Real-world outcomes for PRRT in patients with well differentiated gastroenteropancreatic neuroendocrine tumours

      ea0114oc2
    • Impact of PRRT on quality of life in gastroenteropancreatic neuroendocrine tumours

      ea0114oc3
    • Efficacy of somatostatin analogues versus other systemic therapies as first-line palliative treatment for patients with advanced, grade 2, well-differentiated neuroendocrine tumours of extra-pulmonary origin with a Ki-67 index between 10% and 20%

      ea0114oc4
  • Poster Presentations
  • • A qualitative study exploring the impact of gastrointestinal symptoms and malnutrition on the daily lives of patients living with neuroendocrine tumours (DIGEST)

      ea0114p1
    • Exploring the impact of dietary interventions for people with NETs: a scoping review

      ea0114p2
    • Sheffield teaching hospitals NHS foundation trust ENETS centre of excellence (ENETS COE) service evaluation of the inpatient 72-hour fasts for insulinoma: is continuous glucose monitoring the missing pre-test tool?

      ea0114p3
    • De-novo versus transformed prostate neuroendocrine carcinoma: a population-based study of 1,326 patients

      ea0114p4
    • Hemicolectomy or appendectomy for appendiceal neuroendocrine tumours sized 1-2 cm? a retrospective population-based study of 1,581 patients

      ea0114p5
    • An update of the case controlled national pilot for liver transplantation in patients with neuroendocrine tumour (NETs) liver metastases between August 2021 and 31st July 2025

      ea0114p6
    • Metastatic neuroendocrine tumour (NET) of the kidney: a case report

      ea0114p7
    • Central mesenteric lymph node resection in stage 4 small intestine NET

      ea0114p8
    • Demographic and clinical characteristics of patients undergoing surgery for pancreatic neuroendocrine tumours (PanNET): a retrospective population-based analysis of 11,934 patients comparing England and the USA

      ea0114p9
    • Chemotherapy use and its effect on overall survival in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN): a population based study of 63,911 patients

      ea0114P10
    • Persistent Haematological Toxicity After PRRT in Neuroendocrine Tumours: A 10-Year Regional UK Experience

      ea0114P11
    • Evaluation of the real-world use of hormone replacement therapy (HRT) in women with neuroendocrine cancers in sheffield teaching hospitals european neuroendocrine tumour centre of excellence

      ea0114P12
    • Clinical risk factors for micronutrient deficiencies in patients with gastroenteropancreatic neuroendocrine tumours: a real-world evaluation

      ea0114P13
    • A novel activating somatic EPAS1 variant in the hypoxia signalling pathway in a patient with paraganglioma and sickle cell disease

      ea0114P14
    • Real-world survival outcomes following lutetium-177 dotatate PRRT in gastroenteropancreatic neuroendocrine tumours: a 138-patient UK experience

      ea0114P15
    • Treatment of patients with low-grade neuroendocrine tumours: the impact of conventional chemotherapy on progression-free survival in low-grade gastroenteropancreatic neuroendocrine tumours

      ea0114P16
    • Real-world outcomes of capecitabine and temozolomide in neuroendocrine tumours: a single-institution experience

      ea0114P17
    • Case report: palliative radiotherapy in subcutaneous metastases from a neuroendocrine carcinoma

      ea0114P18
    • Real world outcomes for patients with high grade neuroendocrine neoplasms at Guy's Cancer Centre

      ea0114P19
    • Avoidable consequences of nutritional deficiencies: a case series of vitamin deficiencies secondary to neuroendocrine tumours and their treatment

      ea0114P20
    • Late relapse of gastroenteropancreatic neuroendocrine tumours after curative resection: royal marsden experience

      ea0114P21
    • Recurrence of cyclical ACTH-dependent cushing's syndrome secondary to thymic NET

      ea0114P22
    • Special considerations in patients with neuroendocrine tumours referred for PRRT

      ea0114P23
    • Copy number analysis through shallow whole genome sequencing of cell free DNA for neuroendocrine neoplasia monitoring

      ea0114P24
    • Hypoglycaemia in later life: a case highlighting diagnostic and management challenges

      ea0114P25
    • Relapse after resection of small bowel neuroendocrine tumours: frequency, time to relapse and post-relapse survival in a cohort of patients from the west yorkshire neuroendocrine tumour service. time to reconsider post-resection follow up?

      ea0114P26
    • Case review - successful management of highly complex NET patients depends on the skills of MDTs

      ea0114P27
    • Parathyroidectomy in multiple endocrine neoplasia patients: cohort analysis of clinical outcomes

      ea0114P28
    • Outcomes of surgical resection for small bowel neuroendocrine tumors: a single-center recent experience

      ea0114P29
    • Genetic susceptibility in metastatic adrenocortical carcinoma: a case-based insight

      ea0114P30
    • Managing the crossroads of ectopic cushing's syndrome and sarcoidosis: a case report of multimodal therapeutic challenges

      ea0114P31
    • AI-guided stratification of PRRT candidates: insights from current evidence and future directions

      ea0114P32
    • Ai to flag SSTR imaging patterns predictive of poor PRRT outcomes

      ea0114P33